Neoclease
- Biotech or pharma, therapeutic R&D
Neoclease is pioneering next-generation gene editing with AI-designed nucleases built for precision, performance, and delivery. Unlike legacy approaches that leverage a single enzyme across the entire human genome, we generate novel gene editors optimized for a specific gene target—unlocking therapeutic potential where others fall short.
Our proprietary platform leverages generative AI and structural biology to design compact, efficient, and ultra-specific nucleases tailored to individual disease genes. Starting with a knockout of LRRK2 to slow or halt Parkinson’s progression, we’re building a pipeline of programmable editors for high-impact neurologic and genetic diseases.
Supported by leading academic and industry advisors, Neoclease is backed by award-winning biotech programs and partners. We're headquartered in Boston and rapidly advancing toward preclinical validation of our first candidates.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}